712313-35-4

712313-35-4 structure

Name: HAMI 3379
Chemical Name: 3-[(3-carboxycyclohexyl)carbamoyl]-4-[3-[4-(4-cyclohexyloxybutoxy)phenyl]propoxy]benzoic acid
CAS Number: 712313-35-4
Molecular Formula: C₃₄H₄₅NO₈
Molecular Weight: 595.723
Catalog: Signaling Pathways GPCR/G Protein Leukotriene Receptor
Create Date: 2016-12-17 21:20:01
Modify Date: 2025-08-25 00:25:06
HAMI 3379 is a potent and selective Cysteinyl leukotriene (CysLT2) receptor antagonist[1]. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury, and attenuates microglia-related inflammation[2].

Name	3-[(3-carboxycyclohexyl)carbamoyl]-4-[3-[4-(4-cyclohexyloxybutoxy)phenyl]propoxy]benzoic acid
Synonyms	hami3379 3-[(3-Carboxycyclohexyl)carbamoyl]-4-(3-{4-[4-(cyclohexyloxy)butoxy]phenyl}propoxy)benzoic acid Benzoic acid, 3-[[(3-carboxycyclohexyl)amino]carbonyl]-4-[3-[4-[4-(cyclohexyloxy)butoxy]phenyl]propoxy]-

Description	HAMI 3379 is a potent and selective Cysteinyl leukotriene (CysLT2) receptor antagonist[1]. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury, and attenuates microglia-related inflammation[2].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> GPCR/G Protein >> Leukotriene Receptor Research Areas >> Inflammation/Immunology Research Areas >> Neurological Disease
Target	CysLT2
In Vitro	In a CysLT2 receptor reporter cell line, HAMI 3379 antagonizes leukotriene D4- (LTD4-) and leukotriene C4- (LTC4-) induced intracellular calcium mobilization with IC50 values of 3.8 nM and 4.4 nM, respectively. In contrast, HAMI 3379 exhibits very low potency on a recombinant CysLT1 receptor cell line (IC50>10000 nM)[1].
In Vivo	HAMI 3379 (ip; 0.025-0.4 mg/kg; 24 hours) attenuates the acute brain injury 24 hours after middle cerebral artery occlusion (MCAO) with effective doses of 0.1-0.4 mg/kg and a therapeutic window of ∼1 hour. It attenuates the neurological deficits, and reduces infarct volume, brain edema, and neuronal loss and degeneration 24 and 72 hours after MCAO[2]. HAMI 3379 (infused into the aortic cannula at a rate of 1% of the total flow rate; 0.01, 0.1, 1 μM; 20 min) concentration-dependently inhibits and reverses the LTC4-induced perfusion pressure increase and contractility decrease[1]. Animal Model: Male Sprague-Dawley rats (250-300 g) after MCAO[2] Dosage: 0.025, 0.05, 0.1, 0.2, 0.4 mg/kg Administration: IP; 24 hours Result: Attenuated the acute brain injury 24 hours after MCAO with effective doses of 0.1-0.4 mg/kg and a therapeutic window of ∼1 hour.
References	[1]. Wunder F, et al. Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor. Br J Pharmacol. 2010 May;160(2):399-409. [2]. Zhang XY, et al. HAMI 3379, a CysLT2 receptor antagonist, attenuates ischemia-like neuronal injury by inhibiting microglial activation. J Pharmacol Exp Ther. 2013 Aug;346(2):328-41.

Density	1.2±0.1 g/cm3
Boiling Point	797.7±60.0 °C at 760 mmHg
Molecular Formula	C₃₄H₄₅NO₈
Molecular Weight	595.723
Flash Point	436.3±32.9 °C
Exact Mass	595.314514
PSA	131.39000
LogP	6.48
Vapour Pressure	0.0±2.9 mmHg at 25°C
Index of Refraction	1.587

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

1245653-57-9	712313-35-4
1010441-14-1	1242770-52-0
4233-20-9	1217827-88-7
138500-89-7	70793-08-7
37488-70-3	77901-14-5
915230-49-8	1823462-46-9